Moleculin Biotech, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $6.75
- 52-Week Range
- $3.22 – $227.00
- Market Cap
- $8.42M
- P/E (TTM)
- 0.04
- EPS (TTM)
- 179.60
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.57
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -89.99%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 1.37
- Debt/Equity
- 0.01
- Total Debt
- $107.00K
- Free Cash Flow
- $-17.26M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-14.65K
Market Snapshot
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing oncology drug candidates for resistant and difficult-to-treat tumors. The company focuses on novel anti-tumor agents targeting highly refractory cancers, including glioblastoma, pancreatic cancer, and acute myeloid leukemia. Their pipeline includes small molecules designed to disrupt multiple tumor defense mechanisms simultaneously.